Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib, dose escalation, placebo controlled study of oral formulation of Foralumab to healthy volunteers for the treatment of non-alcoholic steatohepatitis or fatty liver disease (NASH)

Trial Profile

A Phase Ib, dose escalation, placebo controlled study of oral formulation of Foralumab to healthy volunteers for the treatment of non-alcoholic steatohepatitis or fatty liver disease (NASH)

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 01 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Foralumab (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions
  • Sponsors Tiziana Life Sciences
  • Most Recent Events

    • 01 May 2019 According to a Tiziana Life Sciences media release, Upon completion, the safety data from ongoing phase 1 trial with nasal administration will be provided to FDA as part of the revised IND for oral administration of enteric-coated capsules of foralumab in healthy volunteers. A further announcement will be made in due course following receipt of a response from FDA.
    • 01 May 2019 Status changed from planning to suspended, as reported in a Tiziana Life Sciences media release.
    • 01 May 2019 FDA also advised to cross-reference the submitted IND with nasal administration. Accordingly, the company has withdrawn the current IND to include safety data from the ongoing trial with nasal administration and adequately cross-reference the IND for nasal administration with solution of foralumab.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top